agsandrew / Shutterstock.com
The new CRISPR-Cas9 gene-editing system is set to revolutionise the treatment of genetic diseases, but there’s a fight to secure rights to the platform. LSIPR takes a look at the major players in this exciting technology area, and what patent disputes may arise as it develops.
Research into genome-editing technologies has progressed to a point where we can read the strains of DNA that exist in almost every cell of our bodies as if they were on a word processor and take faulty, disease-causing genes out of a sequence and replace them with functioning ones.
The latest method of this so-called gene-editing technology is called CRISPR-Cas9. CRISPR-Cas9 gets its name from the clustered, regularly interspaced, short palindromic repeats (CRISPRs) in the DNA sequence, and the CRISPR-associated protein 9 (Cas9), which makes cuts in the specifically chosen locations in the strand.
Dubbed a ‘search and replace’ function for DNA, CRISPR-Cas9 allows researchers to easily make precise changes to a DNA sequence.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
CRISPR, patent, patent applications, DNA,
